SCHEDULE 13G: Morgan Stanley Discloses Significant Stake in Sage Therapeutics, Holding 7.4% of Common Stock

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed beneficial ownership of 7.4% of Sage Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Morgan Stanley, along with its wholly-owned subsidiary Morgan Stanley & Co. LLC, has filed a Schedule 13G indicating beneficial ownership in Sage Therapeutics, Inc.
• As of December 31, 2024, Morgan Stanley beneficially owned an aggregate of 4,542,992 shares of Sage Therapeutics common stock, representing 7.4% of the class.
• Morgan Stanley holds shared voting power over 4,439,775 shares and shared dispositive power over 4,542,992 shares.
• Morgan Stanley & Co. LLC, a broker-dealer, beneficially owned 3,394,815 shares, representing 5.5% of the class, with both shared voting and dispositive power over these shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Sage Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or forward-looking statements that would influence sentiment.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical or biotechnology sectors. It indicates a significant investment by a major financial institution in Sage Therapeutics.

Related Party Transactions

• The securities reported by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley & Co. LLC, which is a wholly-owned subsidiary of Morgan Stanley. This indicates an internal relationship between the reporting entities.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake in Sage Therapeutics, which can influence market perception and trading activity.

Key Dates

Keywords

Sage Therapeutics, Morgan Stanley, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing, Investment, Pharmaceuticals, Biotechnology